Promising KRAS-targeting drug daraxonrasib doubles survival in late-stage pancreatic cancer
Daraxonrasib, a KRAS-targeting drug for stage 4 pancreatic cancer, doubled survival in trials (6.7 to 13.2 months) and is being provided through an Extended Access Program ahead of FDA approval; nine Intermountain Health patients are enrolled. It is not a cure and carries side effects like rash, diarrhea, and mouth sores.